Collectively, these observations suggest that an intervention designed to combat the demise in insulin sensitivity that begins the pathological journey to cardiometabolic diseases including T2D should be prescribed with precision to elicit a PAE of exercise on insulin sensitivity that can serve as a surrogate for pharmaceutical intervention or, in cases where such intervention is necessary, an adjunct to it [104]. Here, INS is linked to type 2 diabetes mellitus.